drugset / Trial / NCT01927965

Study of Minnelide™ in Patients With Advanced GI Tumors

NCT01927965

Phase 1 Completed 45 enrolled Minneamrita Therapeutics LLC
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of Minnelide™ and to establish the dose of Minnelide™ recommended for future phase 2 protocol

Timeline

Start
2013-08
Primary completion
2016-10
Completion
2016-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Minnelide Small molecule Intravenous

Indications

No indication recorded.